“…Infarct volume size [6,34,37,38,40,41,44,47,48], intracranial volume reserve [6,43,49], infarct permeability area [40], severity of ischemia [34,50], collateral supply [39,48], clot burden [39,48], presence of a prominent anterior temporal artery on imaging [51], lower extracellular levels of nontransmitter amino acids in the perilesional tissue [33], multimodality monitoring to assess cerebral autoregulation [45,52], impairment of autonomic regulation [53], specific electroencephalographic patterns [54,55], and pathologic brainstem auditory evoked potential responses [46] have all been proposed as potential biomarkers of developing MMI. Several different studies strived to identify the most accurate methods for quantifying the infarct extent, collateral supply, and surrogates for pre-existing atrophy.…”